---
layout: default
title: Trifluoperazine
description: "Trifluoperazine çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 1 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 185
evidence_level: L5
indication_count: 1
---

# Trifluoperazine

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>1</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Trifluoperazineï¼šå¾ç²¾ç¥ç—…ç‹€æ…‹åˆ°èºé¬±ç—‡èºç—‡æœŸ

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Trifluoperazine å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Trifluoperazine (ä¸‰æ°Ÿé™ªæ‹‰è¾›) åŸæœ¬ç”¨æ–¼æ²»ç™‚ç²¾ç¥ç—…ç‹€æ…‹åŠè¡Œç‚ºéšœç¤™ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**èºé¬±ç—‡èºç—‡æœŸ (manic bipolar affective disorder)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **20 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ç²¾ç¥ç—…ç‹€æ…‹ã€å™å¿ƒå˜”åã€æ”»æ“Šæ€§èˆ‡ç ´å£æ€§è¡Œç‚ºéšœç¤™ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | manic bipolar affective disorder |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.51% |
| è­‰æ“šç­‰ç´š | L3 (æœ‰é–“æ¥æ–‡ç»è­‰æ“š) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 47 å¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Trifluoperazine æ˜¯ä¸€ç¨®å…¸å‹æŠ—ç²¾ç¥ç—…è—¥ç‰©ï¼ˆphenothiazine é¡ï¼‰ï¼Œå…¶ä½œç”¨æ©Ÿè½‰æ”¯æŒåœ¨èºç—‡æœŸçš„æ‡‰ç”¨ï¼š

1. **å¤šå·´èƒº D2 å—é«”é˜»æ–·**ï¼šæŠ‘åˆ¶ä¸­è…¦é‚Šç·£ç³»çµ±çš„å¤šå·´èƒºéåº¦æ´»åŒ–
2. **é®éœä½œç”¨**ï¼šæ¸›å°‘èºå‹•ã€æ”»æ“Šæ€§è¡Œç‚º
3. **æŠ—ç²¾ç¥ç—…ä½œç”¨**ï¼šæ”¹å–„ç²¾ç¥ç—…æ€§ç—‡ç‹€ï¼ˆå¦‚å¦„æƒ³ã€å¹»è¦ºï¼‰

èºç—‡æœŸå¸¸ä¼´éš¨ç²¾ç¥ç—…æ€§ç—‡ç‹€ï¼Œå…¸å‹æŠ—ç²¾ç¥ç—…è—¥ç‰©åœ¨éå…¸å‹è—¥ç‰©å•ä¸–å‰æ˜¯èºç—‡æ€¥æ€§æœŸçš„æ¨™æº–æ²»ç™‚é¸æ“‡ä¹‹ä¸€ã€‚

## è‡¨åºŠè©¦é©—è­‰æ“š

ç›®å‰ç„¡é‡å°èºé¬±ç—‡èºç—‡æœŸçš„å°ˆé–€è‡¨åºŠè©¦é©—ï¼Œä½†æœ‰å¤šç¯‡æ–‡ç»æ”¯æŒå…¶åœ¨èºç—‡æœŸçš„ä½¿ç”¨ã€‚

## æ–‡ç»è­‰æ“š

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [14309092](https://pubmed.ncbi.nlm.nih.gov/14309092/) | 1965 | Clinical Study | Int J Neuropsychiatry | æ¯”è¼ƒ Haloperidol èˆ‡ Trifluoperazine åœ¨ç²¾ç¥åˆ†è£‚ç—‡åŠèºç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆ |
| [24943390](https://pubmed.ncbi.nlm.nih.gov/24943390/) | 2014 | Survey | J Clin Psychopharmacol | çƒå¹²é”ç²¾ç¥ç—…é™¢è™•æ–¹æ¨¡å¼ï¼šTrifluoperazine èˆ‡ Carbamazepine ä½µç”¨æ²»ç™‚èºé¬±ç—‡ä½” 45% |
| [17017818](https://pubmed.ncbi.nlm.nih.gov/17017818/) | 2006 | Review | J Clin Psychiatry | å…¸å‹èˆ‡éå…¸å‹æŠ—ç²¾ç¥ç—…è—¥ç‰©åœ¨èºé¬±ç—‡ç„¦æ…®ç—‡ç‹€çš„ç™‚æ•ˆå›é¡§ |
| [970489](https://pubmed.ncbi.nlm.nih.gov/970489/) | 1976 | Case Study | Am J Psychiatry | æ¢è¨å¤šå·´èƒºæ©Ÿè½‰åœ¨èºç—‡ä¸­çš„è§’è‰² |
| [3935307](https://pubmed.ncbi.nlm.nih.gov/3935307/) | 1985 | Case Report | Can J Psychiatry | é’å°‘å¹´èºé¬±ç—‡æ¡ˆä¾‹ï¼Œä½¿ç”¨ Trifluoperazine æ²»ç™‚ |

## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å…§è¡›è—¥è¼¸å­—ç¬¬002368è™Ÿ | ç¦è·¯æ–°1å…¬çµ² | éŒ åŠ‘ | æ„è­˜é‹å‹•æ©Ÿèƒ½äº¢é€²å¼•èµ·ä¹‹æ€¥æ…¢æ€§ç²¾ç¥ç—… |
| è¡›ç½²è—¥è£½å­—ç¬¬002672è™Ÿ | æƒ é®å¯§ç³–è¡£éŒ  | ç³–è¡£éŒ  | ç²¾ç¥ç—…ç‹€æ…‹ã€å™å¿ƒå˜”åã€æ”»æ“Šæ€§èˆ‡ç ´å£æ€§è¡Œç‚ºéšœç¤™ |
| è¡›ç½²è—¥è£½å­—ç¬¬032029è™Ÿ | "å¼·ç”Ÿ"å¯Œç¥¿éœè†œè¡£éŒ 5æ¯«å…‹ | è†œè¡£éŒ  | ç²¾ç¥ç—…ç‹€æ…‹ã€å™å¿ƒå˜”åã€æ”»æ“Šæ€§èˆ‡ç ´å£æ€§è¡Œç‚ºéšœç¤™ |
| è¡›ç½²è—¥è£½å­—ç¬¬035165è™Ÿ | ç¦æ¨‚éœè† å›Š2å…¬çµ² | è† å›ŠåŠ‘ | ç²¾ç¥ç—…ç‹€æ…‹ã€å™å¿ƒå˜”åã€æ”»æ“Šæ€§èˆ‡ç ´å£æ€§è¡Œç‚ºéšœç¤™ |

## å®‰å…¨æ€§è€ƒé‡

- **éŒé«”å¤–ç—‡å€™ç¾¤ (EPS)**ï¼šå…¸å‹æŠ—ç²¾ç¥ç—…è—¥ç‰©çš„ä¸»è¦å‰¯ä½œç”¨
- **é²ç™¼æ€§é‹å‹•éšœç¤™ (Tardive dyskinesia)**ï¼šé•·æœŸä½¿ç”¨é¢¨éšª
- **ç¥ç¶“æƒ¡æ€§ç—‡å€™ç¾¤ (NMS)**ï¼šç½•è¦‹ä½†åš´é‡çš„ä¸è‰¯åæ‡‰
- **ä¸»è¦äº¤äº’ä½œç”¨ (Major)**ï¼š
  - Bupropionï¼ˆé™ä½ç™²ç™‡é–¾å€¼ï¼‰
  - Morphineï¼ˆå¢å¼·ä¸­æ¨æŠ‘åˆ¶ï¼‰
  - Metoclopramideï¼ˆå¢åŠ éŒé«”å¤–ç—‡ç‹€é¢¨éšªï¼‰
  - Potassium chlorideã€Potassium citrateï¼ˆå¢åŠ è…¸èƒƒé“æ½°ç˜é¢¨éšªï¼‰
  - Dolasetronï¼ˆQT å»¶é•·é¢¨éšªï¼‰
- **ä¸­åº¦äº¤äº’ä½œç”¨ (Moderate)**ï¼š
  - ç³–å°¿ç—…è—¥ç‰©ï¼ˆå¯èƒ½å½±éŸ¿è¡€ç³–æ§åˆ¶ï¼‰
  - æŠ—è†½é¹¼è—¥ç‰©ï¼ˆå¢åŠ æŠ—è†½é¹¼ä½œç”¨ï¼‰
  - Levofloxacinï¼ˆQT å»¶é•·é¢¨éšªï¼‰

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šConcurrent use of ethanol and phenothiazines may result in additive CNS depression and psychomotor impairment.  Also, ethanol may precipitate dystonic reactions in patients who are taking phenothiazin...
- å»ºè­°ï¼šPatients should be advised to avoid alcohol during phenothiazine therapy.



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Anticholinergic Syndrome** ğŸŸ¡ Moderate
- Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy w...

**Breast Neoplasms** ğŸŸ¡ Moderate
- The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observa...

**Dystonic Disorders** ğŸŸ¡ Moderate
- Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spas...

**Hematologic Diseases** ğŸŸ¡ Moderate
- Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolo...

**Neuroleptic Malignant Syndrome** ğŸŸ¡ Moderate
- The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like hal...

*å¦æœ‰ 11 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Trifluoperazine ä½œç‚ºå…¸å‹æŠ—ç²¾ç¥ç—…è—¥ç‰©ï¼Œåœ¨èºç—‡æœŸçš„ä½¿ç”¨æœ‰æ­·å²æ€§è‡¨åºŠç¶“é©—æ”¯æŒã€‚å¤šç¯‡æ–‡ç»é¡¯ç¤ºå…¶åœ¨èºé¬±ç—‡æ‚£è€…ä¸­çš„æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯åœ¨è³‡æºæœ‰é™çš„åœ°å€ä»æ˜¯é‡è¦çš„æ²»ç™‚é¸æ“‡ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- èˆ‡éå…¸å‹æŠ—ç²¾ç¥ç—…è—¥ç‰©çš„æ¯”è¼ƒç ”ç©¶
- è©•ä¼° EPS åŠä»£è¬å‰¯ä½œç”¨çš„é¢¨éšªæ•ˆç›Šæ¯”
- åˆ¶å®šæ˜ç¢ºçš„åŠ‘é‡å»ºè­°åŠç›£æ¸¬è¨ˆç•«
- è€ƒé‡ä½œç‚ºæ€¥æ€§æœŸæ²»ç™‚è€Œéé•·æœŸç¶­æŒæ²»ç™‚

**è‡¨åºŠæé†’ï¼š**
ç¾ä»£èºç—‡æ€¥æ€§æœŸæ²»ç™‚é¦–é¸é€šå¸¸ç‚ºéå…¸å‹æŠ—ç²¾ç¥ç—…è—¥ç‰©ï¼ˆå¦‚ Olanzapineã€Quetiapineã€Risperidoneï¼‰ï¼ŒTrifluoperazine å¯ä½œç‚ºæ›¿ä»£é¸æ“‡ï¼Œä½†éœ€æ³¨æ„ EPS é¢¨éšªã€‚


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Magnesium Sulfate]({{ "/drugs/magnesium_sulfate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cephalexin]({{ "/drugs/cephalexin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Deoxycholic Acid]({{ "/drugs/deoxycholic_acid/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Berberine]({{ "/drugs/berberine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Butenafine]({{ "/drugs/butenafine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Trifluoperazineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/trifluoperazine/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_trifluoperazine,
  title = {Trifluoperazineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/trifluoperazine/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
